Yayınlar & Eserler

Yayın Ağı
Makaleler 178
Tümü (178)
SCI-E, SSCI, AHCI (154)
SCI-E, SSCI, AHCI, ESCI (156)
ESCI (2)
Scopus (172)
TRDizin (17)
Diğer Yayınlar (4)

1. Comparison of AI chatbot predicted and realworld survival outcomes in hepatocellular carcinoma

Kavak E. E., Erdat E. C., Altundağ Derin Z., Dilli İ., KUBİLAY TOLUNAY P., Öksüzoğlu B., et al.
Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded) identifier identifier identifier

2. Treatment approaches and survival outcomes in elderly colorectal cancer patients: a single-center comparative study

KARAOĞLAN B. B., AKKUŞ E., Kayaalp M., AKYOL C., ERKEK A. B., AKBULUT H., et al.
Clinical and Translational Oncology , cilt.27, sa.5, ss.2292-2306, 2025 (SCI-Expanded) identifier identifier

3. Predicting liver metastasis in colorectal cancer patients using routine biochemical tests enhanced by machine learning

ERDAT E. C., YALÇINER M., Kavak E. E., Dilli I., Cakmak Oksuzoglu O. B., AKBULUT H., et al.
Clinical and Translational Oncology , 2025 (SCI-Expanded) identifier identifier identifier

4. ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis

Yekeduz E., KÖKSOY E. B., AKBULUT H., ÜRÜN Y., UTKAN G.
FUTURE ONCOLOGY , cilt.17, sa.03, ss.349-357, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

5. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study

Jazieh A. R., AKBULUT H., Curigliano G., Rogado A., Alsharm A. A., Razis E. D., et al.
JCO GLOBAL ONCOLOGY , cilt.6, ss.1428-1438, 2020 (ESCI, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

6. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

YALÇIN Ş., Dane F., Oksuzoglu B., Ozdemir N. Y., Isikdogan A., ÖZKAN M., et al.
BMC CANCER , cilt.20, sa.1, 2020 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

7. Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study

Yasar H. A., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.2, ss.267-272, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

8. The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients

ALKAN A., ÜRÜN Y., UTKAN G., AKBULUT H., TUNCAY G., ARAS S., et al.
Journal of Oncological Sciences , cilt.6, sa.2, ss.65-70, 2020 (Hakemli Dergi) Sürdürülebilir Kalkınma

9. Immune gene therapy of cancer

AKBULUT H.
TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.50, ss.1679-1690, 2020 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier identifier

10. The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients.

ALKAN A., ÖZTORUN H. S., KARCI E., ÜRÜN Y., TUNCAY G., YAŞAR H. A., et al.
Journal of Oncological Sciences , cilt.6, sa.2, ss.65-70, 2020 (TRDizin)

11. Oxidative Stress and Sirtuin2 Changes in Different Parts of the Brain in Aging: Protective Effect of Melatonin

AKBULUT K. G., Aktan A. K., Abgarmi S. A., AKBULUT H.
ACTA PHYSIOLOGICA , cilt.227, ss.91, 2019 (SCI-Expanded) identifier

12. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study

ÜRÜN Y., Yasar H. A., TURNA Z. H., Esin E., Sedef A. M., Alkan A., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.25, sa.7, ss.1658-1664, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

13. The Role of Tumor Microenvironment in Genomic Instability of Malignant Tumors

SONUGÜR F. G., AKBULUT H.
FRONTIERS IN GENETICS , cilt.10, 2019 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier

14. A Bicistronic Adenoviral Vector Carrying Cytosine Deaminase and Granulocyte-Macrophage Colony-Stimulating Factor Increases the Therapeutic Efficacy of Cancer Gene Therapy

AKBULUT H., ÇÖLERİ CİHAN A., ŞAHİN G., Tang Y., Icli F.
HUMAN GENE THERAPY , cilt.30, sa.8, ss.999-1007, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

15. Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer

Gunay F. S. D., KIRMIZI B. A., ENSARİ A., Icli F., AKBULUT H.
CLINICAL COLORECTAL CANCER , cilt.18, sa.2, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

16. Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome

Keskin H., Cadirci K., Demirkazık A., Akbulut H., Yalçın B.
Biomarkers in Cancer , cilt.11, 2019 (Hakemli Dergi) Creative Commons License identifier

17. Recent advances in cancer stem cell targeted therapy

AKBULUT H., BABAHAN C., Abgarmi S. A., Ocal M., Besler M.
Critical Reviews in Oncogenesis , cilt.24, sa.1, ss.1-20, 2019 (Scopus) Sürdürülebilir Kalkınma identifier identifier

18. Neuroprotective Effects of Sirt2 Inhibition In Aging

Aktan A. K., AKBULUT K. G., AKBULUT H.
ACTA PHYSIOLOGICA , cilt.225, ss.30, 2018 (SCI-Expanded) identifier

19. Age-Related Changes in the Oxidative Stress, Apoptosis, SIRT2 and Autophagy in the Cerebral Cortex: Protective Effects of Melatonin

AKBULUT K. G., Keskin-Aktan A., Abgarmi S. A., AKBULUT H.
ACTA PHYSIOLOGICA , cilt.225, ss.37, 2018 (SCI-Expanded) identifier

20. Risk factors for thrombosis risk in patients with cancer

TURAN D., YAŞAR H. A., Aksu O. B., KÖKSOY E. B., UTKAN G., AKBULUT H., et al.
Journal of Oncological Sciences , cilt.4, sa.3, ss.130-133, 2018 (Hakemli Dergi) Sürdürülebilir Kalkınma

21. Diagnostic serum vitamin D level is not a reliable prognostic factor for resectable breast cancer

Kaya D. M., Orturk B., Kubilay P., Onur H., UTKAN G., ÇAY ŞENLER F., et al.
FUTURE ONCOLOGY , sa.15, ss.1461-1467, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

22. The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.

AKBULUT H., Ocal M., Sonugur F. G., Abgarmi S. A., BABAHAN C., Akay B., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

23. The effects of melatonin and curcumin on the expression of SIRT2, Bcl-2 and Bax in the hippocampus of adult rats

Keskin-Aktan A., Akbulut K. G., Yazici-Mutlu C., Sonugür F. G., Ocal M., Akbulut H.
BRAIN RESEARCH BULLETIN , ss.306-310, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

24. The Effects of Curcumin Administration on Hippocampal SIRT2, BCL-2, BAX And BIM Expressions in Young and Aged Rats

Aktan A. K., AKBULUT K. G., AKBULUT H.
ACTA PHYSIOLOGICA , cilt.221, ss.25-26, 2017 (SCI-Expanded) identifier

25. Significance of tumour-infiltrating lymphocytes (TILs) in gastric carcinomas: Association of PD-L1 and PD-1 expression with prognostic parameters and survival

Arman A. F., Yasar H. A., Savas B., AKBULUT H., ENSARİ A.
VIRCHOWS ARCHIV , cilt.471, 2017 (SCI-Expanded) identifier

26. Vaccination in oncology practice and predictors

Alkan A., Karci E., Yasar A., Tuncay G., KÖKSOY E. B., Urun M., et al.
SUPPORTIVE CARE IN CANCER , cilt.25, sa.9, ss.2677-2682, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

27. The significance of serum leptin level in patients with early stage nonsmall cell lung cancer

Karatas F., YALÇIN B., Sahin S., AKBULUT H., UTKAN G., DEMİRKAZIK A., et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.13, sa.2, ss.204-207, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

28. Aflibercept-related nasal septum perforation

Alkan A., Yucel L., Mizrak D., AKBULUT H.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , cilt.13, sa.2, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

29. A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer

Aktas S. H., AKBULUT H., Yazici O., Zengin N., Akgun H. N., Ustuner Z., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.47, sa.2, ss.399-406, 2017 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier identifier

30. Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients

Alkan A., Yasar A., Karci E., KÖKSOY E. B., Urun M., ÇAY ŞENLER F., et al.
SUPPORTIVE CARE IN CANCER , cilt.25, sa.1, ss.229-236, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

31. Prognostic Importance of Bone Marrow Uptake on Baseline F-18-FDG Positron Emission Tomography in Diffuse Large B Cell Lymphoma

SOYDAL Ç., KÖKSOY E. B., Yasar A., Turgal E., DOĞANAY ERDOĞAN B., AKBULUT H., et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS , cilt.31, sa.10, ss.361-365, 2016 (SCI-Expanded, Scopus) identifier identifier identifier

32. The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC)

AKBULUT H., Ocal M., Sonugur G., AKAY B. N., BABAHAN C., Abgarmi S. A., et al.
ANNALS OF ONCOLOGY , cilt.27, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

33. Medical oncologists' attitudes towards vaccination in oncology practice

Alkan A., Karci E., Yasar A., Tuncay G., Urun M., Koksoy E. B., et al.
ANNALS OF ONCOLOGY , cilt.27, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

34. Breast cancer survivors suffer from persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish Oncology Group (TOG)

Alkan A., Guc Z. G., ÇAY ŞENLER F., YAVUZŞEN T., Onur H., Dogan M., et al.
SUPPORTIVE CARE IN CANCER , cilt.24, sa.9, ss.3747-3755, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

35. A novel fluorescence turn-on coumarin-pyrazolone based monomethine probe for biothiol detection

Babur B., SEFEROĞLU N., Ocal M., SONUGÜR F. G., AKBULUT H., SEFEROĞLU Z.
TETRAHEDRON , sa.30, ss.4498-4502, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

36. Baculoviral vector loaded mesenchymal stem cells as efficient gene therapy tools for cancer treatment

Aktas S. H., Akbulut H., Elçin A. E., Parmaksız M., Keskin A. A., Çöleri Cihan A., et al.
TURKISH JOURNAL OF BIOLOGY , cilt.40, sa.5, ss.1121-1128, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

37. The Effect of Melatonin, Curcumin and Salermide on Sirt2 expression Level of Hippocampus in Middle Aged Rats

AKBULUT K. G., Aktan A. K., Mutlu C. Y., AKBULUT H.
ACTA PHYSIOLOGICA , cilt.215, ss.44, 2015 (SCI-Expanded) identifier

38. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., Saip P., et al.
BREAST CANCER , cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

39. More prognostic factors in early stage breast cancer

Mizrak D., Ozturk B., Kubilay P., AKBULUT H., Onur H.
BREAST , cilt.24, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

40. Effect of tumor hormonal and HER2 status on localization of metastases in recurrent breast cancer

Mizrak D., Onur H., Ozturk B., Kubilay P., AKBULUT H.
BREAST , cilt.24, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

41. Effect of HER2 and hormonal status to FDG uptake on PET/CT imaging in recurrent breast cancer

Mizrak D., Onur H., Ozturk B., Kubilay P., Utkan G., AKBULUT H.
BREAST , cilt.24, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

42. Serum levels of CEA and CA 15-3 in different subtypes of recurrent breast cancer

Mizrak D., Ozturk B., Kubilay P., AKBULUT H., Onur H.
BREAST , cilt.24, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

43. Preoperative systemic therapy for locally advanced breast cancer: single center experience

Mizrak D., Kubilay P., Ozturk B., Onur H., AKBULUT H.
BREAST , cilt.24, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

44. Blood group: is it associated with tumor biology in breast cancer?

Mizrak D., Kubilay P., Ozturk B., AKBULUT H., Onur H.
BREAST , cilt.24, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

45. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer

ÜRÜN Y., UTKAN G., Yalcin B., AKBULUT H., Onur H., Oztuna D., et al.
Experimental Oncology , cilt.37, sa.1, ss.53-57, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

46. Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)

Aykan N. F., YALÇIN Ş., Turhal N. S., Ozdogan M., Demir G., ÖZKAN M., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.26, sa.2, ss.145-153, 2015 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier identifier

47. The role of melatonin, sirtuin2 and FoXO1 transcription factor in the aging process of colon in male rats

AKBULUT K. G., Aktas S. H., AKBULUT H.
BIOGERONTOLOGY , cilt.16, sa.1, ss.99-108, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

48. Cancer patient and hunger

Mizrak D., AKBULUT H.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.30, sa.3, ss.152-157, 2015 (ESCI) Sürdürülebilir Kalkınma identifier identifier

49. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer

Ürun Y., UTKAN G., Yalcin B., AKBULUT H., Onur H., DG O., et al.
Experimental oncology , cilt.37, sa.1, ss.53-7, 2015 (Scopus) identifier identifier identifier

50. Fighting Against Cigarette Smoking Among Medical Students: A Success Story

Icli F., ODABAŞ D., Gonullu U., Sunguroglu K., Akdur R., AKBULUT H., et al.
JOURNAL OF CANCER EDUCATION , cilt.29, sa.3, ss.458-462, 2014 (SCI-Expanded, Scopus) identifier identifier identifier

51. The Relationship Between Common EGFR, BRAF, KRAS Mutations and Prognosis in Advanced Stage Non-Small Cell Lung Cancer with Response to the Treatment in Turkey

Dogan M., DEMİRKAZIK A., Tukun A., SAK S., CEYHAN K., Yalcin B., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.1, ss.1-10, 2014 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier

52. Designing gene therapy vectors targeting tumor cell endothelium Kanserde damar endoteline yönelik gen tedavisi ajanlari{dotless} geliştirilmesi

Özkal Baydin P., AKBULUT H.
Turk Onkoloji Dergisi , cilt.28, sa.4, ss.179-186, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

53. Melatonin Delays Brain Aging by Decreasing the Nitric Oxide Level

Akbulut K. G., Guney S., Cetin F., Akgun H. N., Aktas S. H., AKBULUT H.
NEUROPHYSIOLOGY , cilt.45, sa.3, ss.187-192, 2013 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

54. Perception about influenza and pneumococcal vaccines and vaccination coverage among patients with malignancies and their family members

ÜRÜN Y., AKBULUT H., DEMİRKAZIK A., Senler F. C., Utkan G., Onur H., et al.
JOURNAL OF BUON , cilt.18, sa.2, ss.511-515, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

55. TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases

Deisseroth A., Tang Y., Zhang L., AKBULUT H., Habib N.
CANCER GENE THERAPY , cilt.20, sa.2, ss.65-69, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

56. Smoking Habits of Relatives of Patients with Cancer: Cancer Diagnosis in the Family is an Important Teachable Moment for Smoking Cessation

HAYRAN K. M., Kilickap S., ELKIRAN E. T., AKBULUT H., Abali H., YÜCE D., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.1, ss.475-479, 2013 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

57. Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature

Dogan M., Yalcin B., Ozdemir N. Y., Arslan U. Y., Dogan L., UTKAN G., et al.
MEDICAL ONCOLOGY , cilt.29, sa.3, ss.2021-2026, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

58. ABO and Rh blood groups frequency in women with HER2 positive breast cancer

ÜRÜN Y., Utkan G., Altundag K., Arslan O., Onur H., Arslan U. Y., et al.
JOURNAL OF BUON , cilt.17, sa.3, ss.457-460, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

59. Primary extranodal non-Hodgkin's lymphoma presenting as painful gingival swelling

ÜRÜN Y., Can F., BARIŞ E., AKBULUT H., UTKAN G., Içli F.
Experimental Oncology , cilt.34, sa.2, ss.134-135, 2012 (SCI-Expanded) identifier identifier

60. Melatonin decreases apoptosis in gastric mucosa during aging

AKBULUT K. G., AKBULUT H., Akgun N., Gonul B.
AGING CLINICAL AND EXPERIMENTAL RESEARCH , cilt.24, sa.1, ss.15-20, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

61. Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGF by cultured human tumor cells: A tentative relationship between drug type and tumor cell type response

Aktas S. H., AKBULUT H., Akgun N., Icli F.
CANCER BIOMARKERS , cilt.12, sa.3, ss.135-140, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

62. ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma

ÜRÜN Y., Ozdemir N. Y., UTKAN G., AKBULUT H., SAVAŞ B., Oksuzoglu B., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , sa.12, ss.6097-6100, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

63. Relationship Between Antimetabolite Toxicity and Pharmacogenetics in Turkish Cancer Patients

Dogan M., KARABULUT H. G., Tukun A., DEMİRKAZIK A., UTKAN G., Yalcin B., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.13, sa.4, ss.1553-1556, 2012 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

64. Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group

ÜRÜN Y., Utkan G., YALÇIN Ş., COŞKUN H. Ş., Kocer M., Ozdemir N. Y., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , sa.8, ss.4129-4131, 2012 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

65. Characteristics of Oropharyngeal Candida and Bacterial Colonization in Cancer Patients

ÇAY ŞENLER F., Cakmakci S., Akan O. A., DEMİRKAZIK A., AKBULUT H., Icli F.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.2, ss.113-119, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

66. Angiosarcoma related to immunosuppressive therapy 8 years after renal transplantation

ÜRÜN Y., DOĞAN İ., KİREMİTCİ S., AKBULUT H., Icli F.
ANNALS OF TRANSPLANTATION , cilt.16, sa.4, ss.138-140, 2011 (SCI-Expanded, Scopus) identifier identifier

67. The effect of age and Helicobacter pylori infection on gastric epithelial cell kinetics

Coban S., Soykan I., TÖRÜNER M., AKBULUT H., Atli T., ENSARİ A.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY , cilt.35, sa.10, ss.661-665, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

68. The role of Phe329 in binding of cationic triarylmethane dyes to human butyrylcholinesterase

BİBEROĞLU K., TACAL Ö., AKBULUT H.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS , cilt.511, sa.1-2, ss.64-68, 2011 (SCI-Expanded, Scopus) identifier identifier identifier

69. Assessment of immature teratoma by 18F-FDG PET/CT

ÖZKAN E., Yagci S., Dogan M., Lacin S., KÜÇÜK N. Ö., AKBULUT H.
European Journal of Radiology Extra , cilt.78, sa.3, 2011 (Scopus) identifier

70. Lymphoproliferative Disorders in Individuals With Chronic Hepatitis B and C in the Turkish Population

İDİLMAN R., Bozkus Y., CENGİZ SEVAL G., Mizrak D., ÇINAR K., Ustun Y., et al.
JOURNAL OF MEDICAL VIROLOGY , cilt.83, sa.6, ss.974-980, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

71. The role of serum osteopontin (OPN) as a prognostic and predictive marker in patients with advanced gastric cancer.

Yazici O., AKBULUT H., Akgun N., Utkan G., Yalcin B., Icli F.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

72. The relationship between common EGFR, b-raf, k-ras mutations, and prognosis in advanced-stage NSCLC with response to the treatment

Dogan M., Demirkazik A., Tukun A., AKBULUT H., SAK S., Ceyhan K., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded) identifier

73. Golgi protein 73 (gp73) is a useful tumor marker in patients with colon cancer.

Ozal G., AKBULUT H., Akgun N., Cipe G., Icli F.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

74. The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study.

Turhal N. S., Kilickap S., Yalcin S., Sezgin C., Yamac D., AKBULUT H., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

75. The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK)

AKBULUT H., Altundag M. K., Saip P., COŞKUN H. Ş., Camci C., Ozkan M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

76. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)

Icli F., AKBULUT H., Onur H., Yalcin B., DEMİRKAZIK A., ÇAY ŞENLER F.
BREAST , cilt.20, sa.2, ss.155-157, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

77. Education, economic status and other risk factors in gastric cancer: "a case-control study of Turkish oncology group"

Icli F., AKBULUT H., Yalcin B., Ozdemir F., Isikdogan A., HAYRAN K. M., et al.
MEDICAL ONCOLOGY , cilt.28, sa.1, ss.112-120, 2011 (SCI-Expanded, Scopus) identifier identifier identifier

78. Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: A cross-sectional disease registry study-A Turkish Oncology Group trial

Aykan N., Demir G., Disci R., Yalcin S., Turhal N. S., Ozdogan M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.4, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

79. The Effects of Chronomodulated Therapy with 5 Fluorouracil 5 Fu and Folinic Acid Fa on the Toxicity and Quality of Life in Patients with Advanced Gastric Cancer

YALÇIN B., AKBULUT H., ABDULLAH B., ŞENCAN O., DEMİRKAZIK A., ONUR H., et al.
Biological Rhythm Research , cilt.35, sa.4, ss.259-268, 2010 (Hakemli Dergi)

80. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells

AKBULUT H., Tang Y., Akbulut K. G., Maynard J., Deisseroth A.
GENE THERAPY , cilt.17, sa.11, ss.1333-1340, 2010 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

81. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP

Dincol D., Buyukcelik A., Dogan M., AKBULUT H., Samur M., DEMİRKAZIK A., et al.
MEDICAL ONCOLOGY , cilt.27, sa.3, ss.942-945, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

82. IgA lambda oligoclonal gammopathy in multiple myeloma

Tek I., Mizrak D., Utkan G., TOPRAK S. K., Tutkak H., Buyukcelik A., et al.
TURKISH JOURNAL OF HEMATOLOGY , cilt.27, sa.2, ss.126-127, 2010 (SCI-Expanded, Scopus, TRDizin) identifier identifier

83. The effects of chemotherapeutic drugs on VEGF secretion of solid tumours

AKBULUT H., Aktas S. H., Ozal G., Zengin N., Akgun N., Ustuner Z., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded) identifier

84. Vector prime protein boost vaccination in the setting of myeloablative-induced lymphopenia suppresses growth of leukemia and solid tumors

Han T. H., Tang Y., Park Y. H., Maynard J., Li P., AKBULUT H., et al.
BONE MARROW TRANSPLANTATION , cilt.45, sa.3, ss.550-557, 2010 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

85. The Prognostic Importance of Leucocytosis, Thrombocytosis and Serum Vascular Endothelial Growth Factor (VEGF) Level in Inoperable Non-Small Cell Lung Cancer (NSCLC): A Match-Pair Analysis

DEMİRKAZIK A., Asik M., Yalcin B., Dogan M., Buyukcelik A., Sencan O., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.20, sa.1, ss.14-19, 2010 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier

86. Modification and implementation of NCCN guidelines on colon cancer in the Middle East and North Africa region.

Içli F., AKBULUT H., Bazarbashi S., Kuzu M. A., Mallath M. K., Rasul K. I., et al.
Journal of the National Comprehensive Cancer Network : JNCCN , cilt.8 Suppl 3, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

87. The role of melatonin on gastric mucosal cell proliferation and telomerase activity in ageing

AKBULUT K. G., Gonul B., AKBULUT H.
JOURNAL OF PINEAL RESEARCH , cilt.47, sa.4, ss.308-312, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

88. Vector vaccination and vector targeted chemotherapy in solid tumors

AKBULUT H., Tang Y., Deisseroth A.
Journal of B.U.ON. , cilt.14, sa.SUPPL.1, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

89. COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY

Tatar M., AKBULUT H.
VALUE IN HEALTH , cilt.12, sa.7, 2009 (SCI-Expanded) identifier

90. Vector vaccination and vector targeted chemotherapy in solid tumors

AKBULUT H., Tang Y., Deisseroth A.
JOURNAL OF BUON , cilt.14, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

91. Mutation profile of Turkish gastrointestinal stromal tumor cases: a multicenter study

Kaygusuz G., Suner S., Karatayli E., Bulbul D. G., Ozoran Y., AKBULUT H., et al.
VIRCHOWS ARCHIV , cilt.455, ss.57, 2009 (SCI-Expanded) identifier

92. Effects of oxaliplatin and 5-fluorouracil on the healing of colon anastomoses

ERSOY P. E., AKBULUT H., Moray G.
SURGERY TODAY , cilt.39, sa.1, ss.38-43, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

93. Kolon kanserinde gen tedavisi

BAYDIN P., AKBULUT H.
Türkiye Klinikleri Tıbbi Onkoloji , cilt.2, sa.1, ss.83-90, 2009 (Hakemli Dergi) Sürdürülebilir Kalkınma

94. Breast cancer with diabetes insipidus

DOĞAN M. K., Karakilic E., Oz I., ZORLU A. F., AKBULUT H.
Experimental Oncology , cilt.30, sa.4, ss.324-326, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

95. Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells

AKBULUT H., Tang Y., AKBULUT K. G., Albert J. M., Deisseroth A.
MOLECULAR THERAPY , cilt.16, sa.10, ss.1753-1760, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

96. Exogenous melatonin decreases age-induced lipid peroxidation in the brain

AKBULUT K. G., Gonul B., AKBULUT H.
BRAIN RESEARCH , cilt.1238, ss.31-35, 2008 (SCI-Expanded, Scopus) identifier identifier identifier

97. The impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer

Buyukqeljk A., AKBULUT H., Yalqin B., Encan O., Tek J., Demir O., et al.
Turkish Journal of Cancer , cilt.38, sa.4, ss.175-183, 2008 (Scopus) Sürdürülebilir Kalkınma identifier

98. Combination of vaccine with targeted chemotherapy reduced levels of CSC like (CD44(+)CD24(-) hematopoietic lineage negative {LIN-}) cells and improves outcome of cancer treatment

AKBULUT H., Tang Y., Akbulut K. G., Maynard J., Deisseroth A. B.
JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.15, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

99. Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with sarcomas

Yaman E., Yalcin B., Utkan G., AKBULUT H., Isikdogan A., Sencan O., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.18, sa.2, ss.79-84, 2008 (SCI-Expanded, Scopus, TRDizin) identifier identifier

100. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.

Sencan O., Buyukcelik A., Yalcin B., Boruban M. C., AKBULUT H., DEMİRKAZIK A., et al.
European journal of cancer care , cilt.17, sa.1, ss.26-32, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

101. Alveolar adenoma of the lung

SAK S., KÖSEOĞLU R. D., Demirag F., AKBULUT H., Gungor A.
APMIS , cilt.115, sa.12, ss.1443-1449, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

102. Symptoms or signs due to different chemotherapeutics and their relationship with serum cytokines/VEGF levels in patients with cancer

DEMİRKAZIK A., Yilmaz H., AKBULUT H., Yalcin B., Icli F.
JOURNAL OF CLINICAL ONCOLOGY , cilt.25, sa.18, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

103. Donor lymphocyte infusions from Ad-sig-TAA/ecdCD40L vector prime-TAA/ecdCD40L protein boost (VPP) vaccinated allodonors decrease tumor cell growth post allograft

Deisseroth A. B., Tang Y., AKBULUT H., Maynard J., Petersen L.
JOURNAL OF CLINICAL ONCOLOGY , cilt.25, sa.18, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

104. Opinions of the Turkish population on cancer and being informed for the diagnosis of cancer: An opinion survey

Yalcin B., Yalcin S., Buyukcelik A., Sencan O., Dogan M., Turk M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.25, sa.18, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

105. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

Icli F., AKBULUT H., Utkan G., Yalcin B., Dincol D., Isikdogan A., et al.
JOURNAL OF SURGICAL ONCOLOGY , cilt.95, sa.6, ss.507-512, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

106. Vaccine for Cancer and Infectious Diseases

Deisseroth A. B., Tang Y., AKBULUT H., Maynard J., Pedersen L.
JOURNAL OF IMMUNOLOGY , cilt.178, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

107. Hepatitis B and C seroprevalence in cancer patients: A case control study Kanserli hastalarda hepatit B ve C sikliǧi: Vaka kontrol çalişmasi

Utkan G., AZAP A., Muallaoǧlu S., Tokluoǧlu S., Durnali A. G., Arslan Ü. Y., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.16, sa.3, ss.103-107, 2006 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

108. The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study

Dogan M., Demirkazik A., Konuk N., Yalcin B., Buyukcelik A., Utkan G., et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS , cilt.21, sa.4, ss.206-210, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

109. Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer

Tang Y., AKBULUT H., Maynard J., Petersen L., Fang X., Zhang W., et al.
JOURNAL OF IMMUNOLOGY , cilt.177, sa.8, ss.5697-5707, 2006 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

110. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.

Utkan G., Bueyuekcelik A., Yalcin B., AKBULUT H., DEMİRKAZIK A., Dincol D., et al.
Lung cancer (Amsterdam, Netherlands) , cilt.53, sa.3, ss.367-74, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

111. Thrombosis of the pulmonary artery in a patient with mucinous adenocarcinoma

Buyukcelik A., Yalcin B., Utkan G., Icli F., Sanlidilek U., AKBULUT H.
MEDICAL SCIENCE MONITOR , cilt.12, sa.9, 2006 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

112. Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer

AKBULUT H., Tang Y., Akbulut K. G., Maynard J., Zhang L., Deisseroth A.
MOLECULAR CANCER THERAPEUTICS , cilt.5, sa.8, ss.1975-1985, 2006 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

113. The clinical and pathological features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study

Yalçin B., Zengin N., AYDIN F., Ilhan M., Işikdoǧan A., Demir G., et al.
Turkish Journal of Cancer , cilt.36, sa.3, ss.108-115, 2006 (Scopus) Sürdürülebilir Kalkınma identifier

114. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy

Liu Y., Ye T., Maynard J., AKBULUT H., Deisseroth A.
CANCER GENE THERAPY , cilt.13, sa.4, ss.346-356, 2006 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

115. The efficacy of preoperative cisplatin and 5-flourouracil combination in patients with stage III squamous cell carcinoma of the esophagus

Han S., Yalçin B., AKBULUT H., Ökten I.
Turkish Journal of Cancer , cilt.35, sa.1, ss.26-31, 2005 (Scopus) identifier

116. Frequency of symptoms in patients with advanced cancer

Yalçin B., Büyükçelik A., Şenler F. Ç., UTKAN G., Tek I., Doǧan M., et al.
Turkish Journal of Cancer , cilt.35, sa.4, ss.177-180, 2005 (Scopus) Sürdürülebilir Kalkınma identifier

117. DNA analysis and DNA ploidy in gastric cancer and gastric precancerous lesions

Yasa M., Bektas A., Yukselen V., AKBULUT H., Camci C., Ormeci N.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , cilt.59, sa.9, ss.1029-1033, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

118. Expression of P53 protein and DNA flow cytometry in gastric adenocarcinoma: Implications in patients treated with adjuvant etoposide, adriamycin and cisplatin

Buyukcelik A., Onur H., AKBULUT H., Yalcin B., ENSARİ A., Utkan G., et al.
TUMORI JOURNAL , cilt.91, sa.4, ss.302-308, 2005 (SCI-Expanded, Scopus) identifier identifier identifier

119. Lymphoscintigraphy in pregnant patients with breast cancer: is it really safe?

Tek I., Buyukcelik A., Yalcin B., AKBULUT H.
ANNALS OF ONCOLOGY , cilt.16, sa.4, ss.674, 2005 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

120. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.

Icli F., AKBULUT H., Uner A., Yalcin B., Baltali E., Altinbas M., et al.
British journal of cancer , cilt.92, sa.4, ss.639-44, 2005 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

121. Frequency of symptoms in patients with advanced cancer

YALÇIN B., ABDULLAH B., ÇAY ŞENLER F., UTKAN G., TEK İ., DOĞAN M., et al.
Turkish Journal of Cancer , cilt.35, sa.4, ss.177-180, 2005 (Scopus) identifier

122. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas

Yalcin B., Pamir A., Buyukcelik A., Utkan G., Abulut H., Demirkazik A., et al.
EXPERIMENTAL ONCOLOGY , cilt.26, sa.4, ss.320-325, 2004 (SCI-Expanded, Scopus) identifier identifier identifier

123. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms

AKBULUT H., Tang Y., Maynard J., Zhang L., Pizzorno G., Deisseroth A.
CLINICAL CANCER RESEARCH , cilt.10, sa.22, ss.7738-7746, 2004 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

124. Overdose of lomustine: Report of two cases

Buyukcelik A., Akbulut H., Yalcin B., Ozdemir F., Icli F.
TUMORI JOURNAL , cilt.90, sa.6, ss.628-629, 2004 (SCI-Expanded, Scopus) identifier identifier identifier

125. Serum vascular endothelial growth factor levels in patients with nonsmall, cell lung cancer

DEMİRKAZIK A., AKBULUT H., Ulger A., Arican A., Ozer I., Acikgoz N., et al.
ANNALS OF SAUDI MEDICINE , cilt.24, sa.6, ss.473-475, 2004 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

126. Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens

Tang Y., Zhang L., Yuan J., AKBULUT H., Maynard J., Linton P., et al.
BLOOD , cilt.104, sa.9, ss.2704-2713, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

127. The effects of chronomodulated therapy with 5-fluorouracil (5-Fu) and folinic acid (Fa) on the toxicity and quality of life in patients with advanced gastric cancer

Yalcin B., AKBULUT H., Buyukcelik A., Sencan O., Demirkazik A., Onur H., et al.
BIOLOGICAL RHYTHM RESEARCH , cilt.35, sa.4-5, ss.259-268, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

128. The opinions of the cancer patients about pain management A questionnaire study

YALÇIN B., ÇAY ŞENLER F., BÜYÜKÇELİK A., UTKAN G., TEK İ., DORUK H., et al.
Turkish Journal of Cancer 34(3):114-117 · July 2004 , cilt.34, sa.3, ss.114-117, 2004 (Scopus) identifier

129. The opinions of the cancer patients about pain management: A questionnaire study

Yalçin B., Şenler F. Ç., Büyükçelik A., UTKAN G., Tek I., Doruk H., et al.
Turkish Journal of Cancer , cilt.34, sa.3, ss.114-117, 2004 (Scopus) Sürdürülebilir Kalkınma identifier

130. Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma

AKBULUT H., Icli F., Yalcin B., DEMİRKAZIK A., Onur H., Buyukcelik A., et al.
EXPERIMENTAL ONCOLOGY , cilt.26, sa.2, ss.149-152, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

131. Thromboembolism in patients with cancer

Büyükçelik A., AKBULUT H.
Turkish Journal of Haematology , cilt.21, sa.1, ss.7-11, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

132. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

Idilman R., Arat M., Soydan E., TÖRÜNER M., Soykan I., Akbulut H., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.11, sa.2, ss.141-147, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

133. A new schedule of mitomycin-C and vinorelbine combination in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes: A phase II study

Yalcin B., ÜNER A., AKBULUT H., Icli F., Buyukcelik A., Isikdogan A., et al.
ANNALS OF ONCOLOGY , cilt.15, ss.42, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

134. The prognostic Importance of Venous Thromboembolism (VT) in cancer patients and its relationship with the ieveis of factor VIII and Vascular Endothelial Growth Factor (VEGF)

DEMİRKAZIK A., Dogan M., Konuk N., AKBULUT H., Yalcin B., Buyukcelik A., et al.
ANNALS OF ONCOLOGY , cilt.15, ss.151, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

135. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells

Zhang L., Tang Y., AKBULUT H., Zelterman D., Linton P., Deisseroth A.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA , cilt.100, sa.25, ss.15101-15106, 2003 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

136. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon

AKBULUT H., Zhang L., Tang Y., Deisseroth A.
CANCER GENE THERAPY , cilt.10, sa.5, ss.388-395, 2003 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

137. Daily variations of plasma malondialdehyde levels in patients with early breast cancer

Akbulut H., Akbulut K., Icli F., Buyukcelik A.
CANCER DETECTION AND PREVENTION , cilt.27, sa.2, ss.122-126, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

138. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.

Akbulut H., ALTUNTAŞ F., Akbulut K., Ozturk G., Cindoruk M., Unal E., et al.
Cytokine , cilt.20, sa.4, ss.184-90, 2002 (SCI-Expanded, Scopus) identifier identifier identifier

139. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma

Zhang L., AKBULUT H., Tang Y., Peng X., Pizzorno G., Sapi E., et al.
MOLECULAR THERAPY , cilt.6, sa.3, ss.386-393, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

140. Effect of granulocyte-macrophage colony-stimulating factor on hepatic regeneration after 70% hepatectomy in normal and cirrhotic rats

EROĞLU A. H., DEMİRCİ S., AKBULUT H., Sever N., DEMİRER S., ÜNAL A. E.
HPB , cilt.4, sa.2, ss.67-73, 2002 (SCI-Expanded) Creative Commons License identifier

141. Radiation recall effect with docetaxel: Is it a barrier for sandwich approach of radiotherapy sequencing in adjuvant breast cancer treatment?

Samur M., Garipaǧaoǧlu M., AKBULUT H.
Turkish Journal of Cancer , cilt.31, sa.2, ss.82-86, 2001 (Scopus) Sürdürülebilir Kalkınma identifier

142. Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma

Emri S., AKBULUT H., Zorlu F., Dincol D., Akay H., Gungen Y., et al.
LUNG CANCER , cilt.33, sa.2-3, ss.109-114, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

143. A randomized trial of four cycles of adjuvant AC (adriamycin plus cyclophosphamide) +/- two cycles of EP (etoposide plus cisplatin) in node positive patients with breast cancer

Icli F., AKBULUT H., Dincol D., Onur H., DEMİRKAZIK A., Cam R., et al.
ANNALS OF ONCOLOGY , cilt.12, sa.7, ss.1011-1013, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

144. The effects of melatonin on humoral immune responses of young and aged rats

Akbulut K., Gonul B., Akbulut H.
IMMUNOLOGICAL INVESTIGATIONS , cilt.30, sa.1, ss.17-20, 2001 (SCI-Expanded, Scopus) identifier identifier identifier

145. Overdosage of pamidronate in a patient with renal cell carcinoma

AKBULUT H., Icli F.
MEDICAL ONCOLOGY , cilt.17, sa.4, ss.340-341, 2000 (SCI-Expanded) identifier identifier identifier

146. Diurnal variations of serum GM-CSF levels

Dincol D., Akbulut H., Buyukcelik A., Icli F.
CYTOKINE , cilt.12, sa.7, ss.1151-1155, 2000 (SCI-Expanded, Scopus) identifier identifier identifier

147. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma

Dincol D., Samur M., Pamir A., Sencan O., Akbulut H., Yalcin B., et al.
CANCER , cilt.88, sa.9, ss.2033-2036, 2000 (SCI-Expanded, Scopus) identifier identifier identifier

148. The efficacy of irinotecan, cisplatin and dacarbazine combination in patients with metastatic colorectal cancer resistant to 5-fluorouracil.

AKBULUT H., Icli F., DEMİRKAZIK A., Yalcin B., Buyukcelik A., Cay F.
ANNALS OF ONCOLOGY , cilt.11, ss.46, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

149. Comparison of 5-fluorouracil-folinic acid and etoposide-doxorubicin-cisplatin chemotherapies in patients with advanced gastric carcinoma: A prospective randomized crossover study, interim analysis.

Sencan O., DEMİRKAZIK A., AKBULUT H., Yalcin B., Icli F.
ANNALS OF ONCOLOGY , cilt.11, ss.70-71, 2000 (SCI-Expanded, Scopus) identifier

150. Clinicopathologic features and prognostic factors of primary extranodal non-Hodgkin's lymphomas in Turkey

Arican A., Dincol D., Akbulut H., Onur H., DEMİRKAZIK A., Cay F., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.22, sa.6, ss.587-592, 1999 (SCI-Expanded, Scopus) identifier identifier identifier

151. Serum "Vascular Endothelial Growth Factor" (VEGF) levels in patients with non-small cell lung cancer (NSCLC)

Demirkazik A., Ozer I., Akbulut H., Arican A., Kulah E., Acikgoz N., et al.
EUROPEAN JOURNAL OF CANCER , cilt.35, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

152. Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer

Eroglu A., Demirci S., Ayyildiz A., Kocaoglu H., Akbulut H., Akgul H., et al.
BRITISH JOURNAL OF CANCER , cilt.80, sa.10, ss.1630-1634, 1999 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

153. Differential effects of pharmacological doses of melatonin on malondialdehyde and glutathione levels in young and old rats

Akbulut K., Gonul B., Akbulut H.
GERONTOLOGY , cilt.45, sa.2, ss.67-71, 1999 (SCI-Expanded, Scopus) identifier identifier identifier

154. Cardiotoxicity of 5-fluorouracil: Two cases with severe bradycardia and review of the literature

Samur M., Arican A., Cakir M., Sencan O., DEMİRKAZIK A., AKBULUT H., et al.
Turkish Journal of Cancer , cilt.29, sa.1, ss.39-41, 1999 (Scopus) identifier

155. The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer

Akbulut H., Icli F., Buyukcelik A., Akbulut K., Demirci S.
JOURNAL OF PINEAL RESEARCH , cilt.26, sa.1, ss.1-8, 1999 (SCI-Expanded, Scopus) identifier identifier identifier

156. Relationship between serum concentration of vascular endothelial growth factor and tumor stage in breast cancer patients

Eroglu A., Demirkazik A., AKBULUT H., Eroglu N.
Journal of B.U.ON. , cilt.4, sa.1, ss.83-85, 1999 (Scopus) identifier

157. The clinical value of flow cytometric DNA content analysis in patients with soft tissue sarcomas

Samur M., Pamir A., AKBULUT H., Erekul S., Saǧlik Y., YILDIZ Y., et al.
Sarcoma , cilt.3, sa.3-4, ss.171-175, 1999 (Scopus) Creative Commons License identifier

158. The effect of two different doses of oral clodronate on pain in patients with bone metastases

Arican A., Içli F., AKBULUT H., Çakir M., Sencan O., Samur M., et al.
MEDICAL ONCOLOGY , cilt.16, sa.3, ss.204-210, 1999 (SCI-Expanded, Scopus) identifier identifier identifier

159. Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil

Icli F., Arican A., Cay F., AKBULUT H., Dincol D., Karaoguz H., et al.
ONCOLOGY , cilt.56, sa.4, ss.297-300, 1999 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

160. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

Icli F., ÇELİK İ., Aykan F., Uner A., DEMİRKAZIK A., Ozet A., et al.
CANCER , cilt.83, sa.12, ss.2475-2480, 1998 (SCI-Expanded, Scopus) identifier identifier identifier

161. Prognostic factors in patients with recurrent breast cancer following mastectomy

Icli F., Cay F., Dincol D., Karaoguz H., Demirkazik A., Akbulut H.
EUROPEAN JOURNAL OF CANCER , cilt.34, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

162. The effect of two different doses of oral clodronate on pain in patients with bone metastases

Ancan A., Icli F., Akbulut H., Cakr M., Sencan O., Samur M., et al.
EUROPEAN JOURNAL OF CANCER , cilt.34, 1998 (SCI-Expanded) identifier

163. A comparison of imipenem monotherapy versus cefoperazone/sulbactam plus amikacin combination treatment in febrile neutropenic cancer patients

Dincol D., Arican A., Aydin F., Samur M., Willke A., AKBULUT H., et al.
CANCER JOURNAL - FRANCE , cilt.11, sa.2, ss.89-93, 1998 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

164. Cisplatin and epirubicin induction chemotherapy followed by chemoradiotherapy in limited stage small cell lung cancer (LS-SCLC)

Cay F., Onat H., Saip P., Kars A., DEMİRKAZIK A., AKBULUT H., et al.
ANNALS OF ONCOLOGY , cilt.9, ss.104, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

165. The prognostic significance of flow cytometric cellular DNA content determination in patients with colorectal carcinoma

AKBULUT H., Dincol D., Aydintug O., Icli F., Karaoguz H., DEMİRKAZIK A., et al.
Turkish Journal of Cancer , cilt.28, sa.2, ss.51-58, 1998 (Scopus) identifier

166. Surgical resection followed by adjuvant chemotherapy in small cell lung cancer with limited disease

Arican A., Dincol D., AKBULUT H., Cay F., Icli F., Karaoguz H., et al.
ANNALS OF ONCOLOGY , cilt.9, ss.105-106, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

167. Myeloprotective effect of high dose medroxyprogesterone acetate on patients receiving cytotoxic chemotherapy

Samur M., Icli F., AKBULUT H., DEMİRKAZIK A., Cay F., Arican A.
Turkish Journal of Cancer , cilt.28, sa.3, ss.118-123, 1998 (Scopus) Sürdürülebilir Kalkınma identifier

168. Effects of high dose medroxyprogesterone acetate on endogenous granulocyte macrophage-colony stimulating factor secretion and bone marrow cellularity in patients under cytotoxic chemotherapy

AYDİN F., DEMİRKAZIK A., Içli F., AKBULUT H., Samur M.
Journal of Chemotherapy , cilt.10, sa.5, ss.394-398, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

169. Cost-effectiveness of radionuclide bone scanning to rule out asymptomatic bone metastases in clinically operable non-small cell lung cancer

Arican A., Dincol D., Samur M., Demirkazlk A., Sencan O., Akbulut H., et al.
EUROPEAN JOURNAL OF CANCER , cilt.33, 1997 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

170. Results of the cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP)+/-bleomycin treatment and evaluation of prognostic factors in aggressive lymphomas in Turkey

Dincol D., AKBULUT H., Icli F., Samur M., Karaoguz H., DEMİRKAZIK A., et al.
ONCOLOGY , cilt.54, sa.5, ss.376-379, 1997 (SCI-Expanded, Scopus) identifier identifier identifier

171. Comparative study of imipenem versus sulperazone plus amikacin in febrile neutropenia

Dincol D., Arican A., Aydin F., Samur M., Willke A., Akbulut H., et al.
EUROPEAN JOURNAL OF CANCER , cilt.33, ss.253, 1997 (SCI-Expanded) identifier

172. Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease - A Turkish experience

Akbulut H., Soykan I., Yakaryilmaz F., Icli F., Aksoy F., Haznedaroglu S., et al.
CANCER , cilt.80, sa.1, ss.8-14, 1997 (SCI-Expanded, Scopus) identifier identifier identifier

173. Malondialdehyde and glutathione in rat gastric mucosa and effects of exogenous melatonin

Akbulut H., Akbulut K., Gonul B.
DIGESTIVE DISEASES AND SCIENCES , cilt.42, sa.7, ss.1381-1382, 1997 (SCI-Expanded, Scopus) identifier identifier identifier

174. Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric

Icli F., Karaoguz H., AKBULUT H., Dincol D., DEMİRKAZIK A., Cay F.
JOURNAL OF SURGICAL ONCOLOGY , cilt.64, sa.4, ss.318-323, 1997 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

175. Two dose levels of ifosfamide in malignant mesothelioma

Icli F., Karaoguz H., Hasturk S., Kurt B., AKBULUT H., Dincol D., et al.
LUNG CANCER , cilt.15, sa.2, ss.207-213, 1996 (SCI-Expanded, Scopus) identifier identifier identifier

176. Serum and tissue zinc concentrations in patients with duodenal ulcers DUODENUM ULSERLI HASTALARDA SERUM VE DOKU CINKO DUZEYLERI

Soykan I., AKBULUT H., YILDIRIM İ. E., Haznedaroglu S.
Turkish Journal of Gastroenterology , cilt.7, sa.1, ss.53-56, 1996 (SCI-Expanded) identifier

177. Results of the cyclophosphamide, adriamycine, vincristine, prednisolon (CHOP) +/- bleomycine treatment and evaluation of prognostic factors in aggressive lymphomas

Dincol D., Icli F., Akbulut H., Samur M., Karaoguz H., Demirkazik A., et al.
EUROPEAN JOURNAL OF CANCER , cilt.31A, ss.784, 1995 (SCI-Expanded) identifier

178. MESNA IFOSFAMIDE, MITOXANTRONE, ETOPOSIDE, BLEOMYCIN, VINCRISTINE, PREDNISONE (MINE-BOP) COMBINATION CHEMOTHERAPY IN THE TREATMENT OF REFRACTORY AND RELAPSED NON-HODGKINS-LYMPHOMA

DINCOL D., ICLI F., KARAOGUZ H., CAY F., ARICAN A., DEMİRKAZIK A., et al.
ACTA ONCOLOGICA , cilt.34, sa.7, ss.937-940, 1995 (SCI-Expanded, Scopus) identifier identifier identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 128

1. Kanser tedavisinde kullanılmak üzere anti_CD47 scFv gen tedavi vektörleri geliştirilmesi

SONUGÜR F. G., Korgan E., BABAHAN C., AKBULUT H.
9. Karadeniz Onkoloji Günleri, Trabzon, Türkiye, 17 - 19 Ekim 2024, (Özet Bildiri)

2. Increased Expression of DNA Damage Inducible Transcript 4 Gene is Associated with Poor Prognosis and “Right-Sidedness” in Colorectal Cancer

demir f. g., TAMAM S., ÇULCU S., SAVAŞ B., AKBULUT H., ÖZDAĞ SEVGİLİ H., et al.
How to bring basic science discoveries to the clinic, 27 Şubat 2024, (Tam Metin Bildiri)

3. INHBA is a potential biomarker and therapeutic target for patients with colorectal cancer

BELDER N., DEMİRKOL CANLI S., TAMAM S., ÇULCU S., SAVAŞ B., AKBULUT H.
November 29 – December 02, 2023 9 th International BAU Drug Design Congress, 29 Kasım - 02 Aralık 2023, (Tam Metin Bildiri)

4. Replication Defective Adenoviral Vectors Decreases the Immunosuppresive Cytokine Expression in Tumor Cells

Zengin İ., SONUGÜR F. G., BABAHAN C., Abdi Abgarmi S., AKBULUT H.
BIO Türkiye Uluslararası Biyoteknoloji Kongresi, İstanbul, Türkiye, 28 Eylül 2023, (Özet Bildiri)

5. Replication Defective Adenoviral Vectors do not induce Apoptosis and Autophagy in endothelial cells

Korgan E., BABAHAN C., SONUGÜR F. G., Abdi Abgarmi S., AKBULUT H.
BIO Türkiye Uluslararası Biyoteknoloji Kongresi, İstanbul, Türkiye, 28 Eylül 2023, (Özet Bildiri)

6. Low-Dose Chemotherapy Inhibits Proangiogenic Factors in Endothelial and Cancer Cells

SONUGÜR F. G., BABAHAN C., AKBULUT H.
BIO Türkiye Uluslararası Biyoteknoloji Kongresi, İstanbul, Türkiye, 28 - 30 Eylül 2023, (Özet Bildiri)

7. Purification Optimization Of A Recombinant Single-Chain Variable Fragment (ScFv) Antibody

BABAHAN C., SONUGÜR F. G., KARAGÖZ Z., YILMAZ E., AKBULUT H.
BIOTürkiye, İstanbul, Türkiye, 28 - 30 Eylül 2023, (Tam Metin Bildiri)

8. Nadir Meme Kanseri Tipleri - Tek Merkez Deneyimi

YAŞAR H. A., KUBİLAY TOLUNAY P., AKBULUT H.
On Targed Master Oncology, Muğla, Türkiye, 21 - 24 Eylül 2023, ss.43-44, (Özet Bildiri)

9. GİST HASTALARINDA İMATİNİB ALTINDA KAN LİPİD DÜZEYİ DEĞİŞİKLİKLERİ

KÖKSOY E. B., KARCI E., ÜRÜN M., YAŞAR H. A., ÖZYURT N., UTKAN G., et al.
22. Ulusal Kanser Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2017, ss.441, (Özet Bildiri)

10. DOWNSTREAM PROSES SÜRECİNDE İNKÜBASYON SICAKLIĞI VE MİKROFİLTRASYON MEMBRANI SEÇİMİNİN REKOMBİNANT ADENOVİRAL VEKTÖR VERİMİNE ETKİSİ

SONUGÜR F. G., BABAHAN C., Abdi Abgarmi S., AKBULUT H.
4.Uluslararası Aşı Bilimi Kongresi, Ankara, Türkiye, 03 Kasım 2022, cilt.1, ss.1, (Tam Metin Bildiri)

11. İLERİ EVRE MALİGNİTELERDE İMMÜNCHECKPOİNT İNHİBİTÖRLERİ İLE EŞ ZAMANLI VERİLEN ANTİHİSTAMİNİKLERİN SAĞKALIM KATKISI İLE İLGİLİ GERÇEK YAŞAM VERİLERİ

Eylemer Mocan E., Yekedüz E., Karataş G., Yazgan S. C., Köksoy E. B., Çay Şenler F., et al.
9. TÜRK TIBBİ ONKOLOJİ DERNEĞİ KONGRESİ, Girne, Kıbrıs (Kktc), 18 - 22 Mayıs 2022, ss.53-54, (Özet Bildiri)

12. Sirolimus Kemopreventif Tedavisi Altındaki Bir PTEN Hamartom Sendromu Olan Bannayan-Riley-Ruvalcaba Sendromu

Eylemer Mocan E., Köksoy E. B., Akbulut H.
9. Türk Tıbbi Onkoloji Derneği Kongresi , Girne, Kıbrıs (Kktc), 18 - 22 Mayıs 2022, ss.196, (Özet Bildiri)

13. İleri evre malignitelerde immüncheckpoint inhibitörleri ile eş zamanlı verilen antihistaminiklerin sağkalım katkısı ile ilgili gerçek yaşam verileri

EYLEMER MOCAN E., YEKEDÜZ E., KARATAŞ G., YAZGAN S. C., KÖKSOY E. B., ÇAY ŞENLER F., et al.
9. Türk Tıbbi Onkoloji Kongresi, Girne, Kıbrıs (Kktc), 18 - 22 Mayıs 2022, ss.53, (Özet Bildiri)

14. İmmünoterapi alan metastatik melanom hastalarında vücut kompozisyonu ve sağkalım arasındaki ilişkinin değerlendirilmesi

KARATAŞ G., YEKEDÜZ E., KİRİŞCİ B., ÇAY ŞENLER F., AKBULUT H.
9. Türk Tıbbi Onkoloji Kongresi, Girne, Kıbrıs (Kktc), 18 - 22 Mayıs 2022, ss.224, (Özet Bildiri)

15. CRP/albumin oranının immün denetim noktası inhibitörü alan metastatik kanser hastalarındaki prognostik rolü

YEKEDÜZ E., YAZGAN S. C., KÖKSOY E. B., AKBULUT H., ÇAY ŞENLER F., DEMİRKAZIK A., et al.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 3 - 07 Kasım 2021, ss.108, (Özet Bildiri)

16. Regorafenib ile tedavi edilen nüks metastatik osteosarkom olgusu

DURSUN B., BALLI S., KALACI E., AKBIYIK I., YEKEDÜZ E., KAVAK E. E., et al.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 3 - 07 Kasım 2021, ss.183-184, (Özet Bildiri)

17. Letrozol ilişkili mediastinal lenfadenopatiler ve pulmoner nodüller

KÖKSOY E. B., YEKEDÜZ E., KALACI E., AKBULUT H., DEMİRKAZIK A.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 3 - 07 Kasım 2021, ss.161, (Özet Bildiri)

18. The impact of COVID-19 pandemic on cancer care: A global collaborative study

Jazieh A. R., AKBULUT H., Curigliano G., Rogado A., Alsharm A. A., Razis E., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri) Creative Commons License Sürdürülebilir Kalkınma identifier

19. The Effect of PD-L1 Expression on Angiogenesis and Invasion in Tumor Cells

BABAHAN C., Abdi Abgarmi S., SONUGÜR F. G., AKBULUT H.
Immuno-Oncology 2019, Barselona, İspanya, 23 Mayıs 2019, ss.6-7, (Özet Bildiri)

20. Oxidative Stress and Sirtuin2 Changes in Different Partsof the Brain in Aging: Protective Effect of Melatonin

AKBULUT K. G., KESKİN AKTAN A., Abgarmi S. A., AKBULUT H.
Turkish Society of Physiological Sciences 45th National Physiology Congress Kuşadası-Aydın, Türkiye, 31 Ekim - 03 Kasım 2019, (Özet Bildiri)

21. Meme Kanserinde Survivin İfadesinin Tamoksifen Direncine Etkisi

DEDE İ., AKBULUT H., KARABÖRK A., ÇETİN Ş.
4th International Symposium on Innovative Approaches in Health and Sports Sciences Proceedings, 22 - 24 Kasım 2019, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

22. The role of pericytes on the efficacy of Bevacizumab in colorectalcancer

Bakırcı M., dost günay f. s., ÇAY ŞENLER F., kırmızı a. b., SAVAŞ B., AKBULUT H.
7th International Congress of Molecular Medicine, 5 - 07 Eylül 2019, (Özet Bildiri)

23. The role of pericytes on the efficacy of Bevacizumab in colorectal cancer

Besler M., Dost Günay F. S., ÇAY ŞENLER F., KIRMIZI B. A., SAVAŞ B., AKBULUT H.
VII. International Congress of Molecular Medicine, 5 - 07 Eylül 2019, (Özet Bildiri)

24. Anti-Angiogenic Treatment Suppresses the Immunosuppressive Cytokine Production in Tumor Cells

Abdi Abgarmi S., BABAHAN C., SONUGÜR F. G., AKBULUT H.
Immuno-Oncology 2019, Barselona, İspanya, 23 Mayıs 2019, (Özet Bildiri)

25. Setüksimab tedavisi ile uzun süre stabil seyretmiş cilt SCC olgusu

ÖZYURT N., GÜRBÜZ M., YAŞAR H. A., KUBİLAY TOLUNAY P., YEKEDÜZ E., KARAALİOĞLU B., et al.
23. Ulusal Kanser Kongresi, Antalya, Türkiye, 17 - 21 Nisan 2019, ss.401, (Özet Bildiri)

26. Nodüler Lenfosit Baskın Hodgkin Lymphoma (NLBHL)’da Kombine İnflamasyon İndeksinin Prognostik Önemi

PAYDAŞ S., ÇAKAR M. K., BARIŞTA İ., SEYDAOĞLU G., PEHLİVAN M., DOĞAN M., et al.
23. Ulusal Kanser Kongresi, Antalya, Türkiye, 17 - 21 Nisan 2019, (Özet Bildiri)

27. Nazofarenks Kanserli Hastalarda Sağkalım İle İlişkili Prognostik Faktörler

YAŞAR H. A., KUBİLAY TOLUNAY P., DEMİRKIRAN A., KARAAĞAÇ M., GÜMÜŞTEPE E., UTKAN G., et al.
23. Ulusal Kanser Kongresi, Antalya, Türkiye, 17 - 21 Nisan 2019, (Özet Bildiri)

28. Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçları- Gerçek Yaşam Verisi

ALKAN A., Sevgen Güç Z., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., et al.
23. Ulusal Kanser Kongresi - 2019, Türkiye, 17 - 21 Nisan 2019, (Özet Bildiri) Sürdürülebilir Kalkınma

29. GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİMETASTATİK PROSTAT KANSERİ (KDMPK)HASTALARINDA 1. BASAMAK ANTİ- ANDROJENTEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ

ALKAN A., SEVGEN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., et al.
23. ULUSAL KANSER KONGRESİ, Antalya, Türkiye, 17 - 21 Nisan 2019, ss.300, (Özet Bildiri) Sürdürülebilir Kalkınma

30. GERIATRIK (≥75 YAŞ), KASTRASYON DIRENÇLI METASTATIK PROSTAT KANSERI (KDMPK) HASTALARINDA 1. BASAMAK ANTI- ANDROJEN TEDAVI SONUÇLARI- GERÇEK YAŞAM VERISI

ALKAN A., Sevgen Güç Z., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., et al.
23. ULUSAL KANSER KONGRESİ - 2019, Türkiye, 17 - 21 Nisan 2019, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

31. Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçları- Gerçek Yaşam Verisi

ALKAN A., SEVGEN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., et al.
23. ULUSAL KANSER KONGRESİ, Antalya, Türkiye, 17 - 21 Nisan 2019, ss.185, (Özet Bildiri) Sürdürülebilir Kalkınma

32. Start of a new Arms Race? The US nuclear Arms Policy in the Trump era

AKBULUT H.
Conference on Radical Break?- American Foreign Policy in the Era of Donald Trump, Tutzing, Almanya, 15 - 17 Aralık 2017, cilt.15, ss.153-186, (Tam Metin Bildiri) identifier

33. Neuroprotective Effects of Sirt2 Inhibition in Aging

KESKİN AKTAN A., AKBULUT K. G., AKBULUT H.
Turkish Society of Physiological Sciences 44, Antalya, Türkiye, 1 - 04 Kasım 2018, (Özet Bildiri)

34. Age-related changes in the oxidative stress, apoptosis,sirtuin 2 and FoxO3a expression in the hippocampus:protective effects of melatonin

KESKİN AKTAN A., Abgarmi S., AKBULUT K. G., AKBULUT H.
14-16 September 2018The QEII Centre, London, UK, 14 - 16 Eylül 2018, (Özet Bildiri)

35. SIRT2 inhibition suppresses the oxidative stress andapoptotic activity, and increases autophagy of cerebralcortex in the aging process.

AKBULUT K. G., KESKİN AKTAN A., Abgarmi S., AKBULUT H.
14-16 September 2018The QEII Centre, London, UK, Londrina, Brezilya, 14 - 16 Eylül 2018, (Özet Bildiri)

36. MIDE KANSERI VE ABO KAN GRUBU İLIŞKISI: ÇOK MERKEZLI, GÖZLEMSEL, VAKA-KONTROL ÇALIŞMASI

YAŞAR H. A., UTKAN G., ÖZDEMİR N., ÇAKMAK ÖKSÜZOĞLU Ö. B., DEDE İ., ÜRÜN Y., et al.
7. Türk Tıbbı Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2018, ss.443, (Özet Bildiri)

37. A bicistronic adenoviral vector carrying cytosine deaminase and GM-CSF genes significantly improves antitumor immunity and overall survival in colon cancer

AKBULUT H., ÇÖLERİ CİHAN A., ŞAHİN G., Tang Y., Deisseroth A., Icli F.
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Illinois, Amerika Birleşik Devletleri, 14 - 18 Nisan 2018, cilt.78, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

38. The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.

AKBULUT H., Öçal M., Sonugür F. G., Babahan C., Abdi Abgarmi S.
ASCO 2018, 1 - 04 Haziran 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

39. Pankreas Kanseri ve ABO Kan Grubu İliskisi: Çok Merkezli, Gözlemsel, Vaka-Kontrol Çalışması

KÖKSOY E. B., UTKAN G., ERGÜN Y., ESİN E., ŞENDUR M. A. N., KARCI GÜNER E., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

40. METASTATİK OLMAYAN KOLOREKTAL ADENOKANSERDE HASTALIKSIZ SAĞKALIM İLE İLGİLİ PREDİKTİF FAKTÖRLERİN DEĞERLENDİRİLMESİ

KARCI E., KÖKSOY E. B., HOCAZADE C., BİLGİN B., ALKAN A., YAŞAR H. A., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2018, (Özet Bildiri)

41. İPILIMUMAB ILE TEDAVI EDILEN MUKOZAL VE UVEAL MALIGN MELANOM HASTALARINDA SAĞKALIM IÇIN PROGNOSTIK FAKTÖRLER: TÜRK ONKOLOJI ÇALIŞMA GRUBU (TOG) ÇALIŞMASI

YAŞAR H. A., TURNA Z. H., ESİN E., SEDEF A. M., ALKAN A., ÇAKMAK ÖKSÜZOĞLU Ö. B., et al.
7. Türk Tıbbı Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2018, ss.150, (Özet Bildiri)

42. Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

Yalcin S., Dane F., Oksuzoglu B., Yildirim N., Isikdogan A., Ozkan M., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 18 - 20 Ocak 2018, cilt.36, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

43. Relationship between metabolic parameters and ras mutation status

KARCI E., SOYDAL Ç., UTKAN G., ÜRÜN Y., AKBULUT H.
30th Annual Congress of the European Association of Nuclear Medicine, 21 - 25 Ekim 2017, cilt.44, ss.696, (Özet Bildiri)

44. Oxidative stress, FOXO3a andBIM expressions in aging cerebral cortex: modulation by curcumin

KESKİN AKTAN A., AKBULUT K. G., AKBULUT H.
2ndInternational Gazi Pharma Symposium Series (GPSS-2017), October 11-13, 2017, GaziUniversity, Turkey. P, 11 - 13 Ekim 2017, (Özet Bildiri)

45. The effects of curcumin administration on hippocampal SIRT2 , BCL-2 BAX and BIM expression in young and aged rats.

KESKİN AKTAN A., AKBULUT K. G., AKBULUT H.
43. Ulusal Fizyoloji Kongresi, Türkiye, 7 - 09 Eylül 2017, (Özet Bildiri)

46. Significance of tumour-infiltrating lymphocytes (TILs) in gastric carcinomas: Association of PD-L1 and PD-1 expression with prognostic parameters and survival

Arman F., YAŞAR H. A., SAVAŞ B., AKBULUT H., ENSARİ A.
European Congress of Pathology, 2 - 06 Eylül 2017, cilt.471, ss.34-35, (Özet Bildiri)

47. Effect of verylow doses of cehmotherapeutic drugs on proangiogenic factors in tumor cells

Öçal M., Sonugür F. G., Babahan C., Abdi Abgarmi S., İÇLİ F., AKBULUT H.
ASCO 2017, 2 - 06 Haziran 2017, (Özet Bildiri)

48. Asingle center analysis of evolving experience with ALPPS procedure: Towards better patient and graft selection

BALCI D., KIRIMKER E. O., ÖZÇELİK M., ÜSTÜNER E., KONCA C., UTKAN G., et al.
12th Biennial E-AHPBA Congress 2017, Mainz, Almanya, 23 - 26 Mayıs 2017, (Özet Bildiri)

49. Tumor associated macrophages to predict the efficacy of bevacizumab plus chemotherapy in patients with advanced colorectal cancer.

AKBULUT H., Gunay F. S. D., Kirmizi B. A., Koksoy E. B., ENSARİ A., Icli F.
53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2017, cilt.35, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

50. Effect of very low doses of chemotherapeutic drugs on proangiogenic factors in tumor cells.

Ocal M., Sonugur F. G., BABAHAN C., Abgarmi S. A., Icli F., AKBULUT H.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2017, cilt.35, (Özet Bildiri) identifier

51. The effects of very low doses of chemotherapeutic drugs on endothelial cells.

Sonugur F. G., Ocal M., BABAHAN C., Abgarmi S. A., Icli F., AKBULUT H.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2017, cilt.35, (Özet Bildiri) identifier

52. Metronomik Kemoterapinin Tümör Hücrelerinde Anjiyogenik Faktör Sentezi Üzerindeki Etkileri

ÖÇAL DEMİRTAŞ M., SONUGÜR F. G., BABAHAN C., Abdi Abgarmi S., AKBULUT H.
22. Ulusal Kanser Kongresi, Antalya, Türkiye, 17 - 23 Nisan 2017, (Özet Bildiri)

53. Evre III Mide kanseri adjuvant tedavisinde dosetaksel- sisplatin- fluorourasil(DCF) rejiminin etkinliği

ALKAN A., Mızrak D., karcı E., YAŞAR H. A., KÖKSOY E. B., Ürün M., et al.
22. Ulusal Kanser Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2017, ss.256-257, (Özet Bildiri)

54. Kalp ve Beyin Metastatik Yassı Hücreli Dil Karsinomu Olgusu

ÜRÜN M., ÖZYURT N., KÖKSOY E. B., YAŞAR H. A., KARCI E., UTKAN G., et al.
22. Ulusal Kanser Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2017, ss.321, (Özet Bildiri)

55. Onkoloji pratiğinde aşılama ve etkileyen faktörler

ALKAN A., karcı E., YAŞAR H. A., Tuncay G., KÖKSOY E. B., Ürün M., et al.
22. Ulusal Kanser Kongresi, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

56. Metronomik Kemoterapinin Endotel Hücre Fonksiyonları Üzerindeki Etkisi

SONUGÜR F. G., BABAHAN C., Abdi Abgarmi S., AKBULUT H.
22. Ulusal Kanser Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2017, (Tam Metin Bildiri)

57. Metastatik Olmayan Kolorektal Adenokanserlerde Lenf Nodu Metastazı İçin Prediktif Faktörlerin Değerlendirilmesi

KARCI E., KÖKSOY E. B., HOCAZADE C., BİLGİN B., ALKAN A., DEDE İ., et al.
22. ULUSAL KANSER KONGRESİ, Antalya, Türkiye, 19 Nisan 2017, ss.242-243, (Özet Bildiri)

58. Evre III Mide Kanseri Adjuvant Tedavisinde Dosetaksel-Sisplatin-Fluorourasil (DCF) Rejiminin Etkinliği

ALKAN A., MIZRAK KAYA D., Karci E., Yasar A., Koksoy E. B., Ürün M., et al.
22. Ulusal Kanser Kongresi, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

59. Prognostic importance of bone marrow uptake on baseline 18F-FDG positron emission tomograpy/computed tomography in diffuse large B-Cell lymphoma

SOYDAL Ç., KÖKSOY E. B., YAŞAR H. A., TURGAL E., DOĞANAY ERDOĞAN B., AKBULUT H., et al.
Annual Congress of the European Association of Nuclear Medicine, 15 - 19 Ekim 2016, cilt.43, ss.317, (Özet Bildiri)

60. The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectalcancer mCRC

AKBULUT H., Öcal M., Sonugür G., AKAY B., Bahahan C., Abgarmi S. A., et al.
ESMO Congress, 7 - 11 Ekim 2016, (Özet Bildiri)

61. TRPredictive factors of lymph node metastasis in patients with non metastatic colorectal Adenocarcinoma

Karcı E., KÖKSOY E. B., ALKAN A., Dede İ., Tuncay G., UTKAN G., et al.
ESMO Congress, 7 - 11 Ekim 2016, (Özet Bildiri)

62. Medical oncologists attitudes towards vaccination in oncology practice

ALKAN A., Karcı E., YAŞAR H. A., Tuncay G., Ürün M., KÖKSOY E. B., et al.
ESMO Congress, 7 - 11 Ekim 2016, (Özet Bildiri) Sürdürülebilir Kalkınma

63. Vaccination in oncology practice and predictors

ALKAN A., KARCI E., YAŞAR H. A., TUNCAY G., ÜRÜN M., KÖKSOY E. B., et al.
ESMO, 7 - 10 Ekim 2016

64. Medical oncologists attitudes towards vaccination inoncology practice

ALKAN A., karcı e., YAŞAR H. A., tuncay g., ürün m., KÖKSOY E. B., et al.
ESMO annual meeting, 7 - 11 Ekim 2016, (Özet Bildiri)

65. Adjuvant concurrent chemoradiotherapy(CRT) plus docetaxelcisplatin-fluorouracil (DCF) versus CRT plus fluorouracil folinic acid (FUFA) in gastric cancer

Alkan A., Mizrak D., Karci E., Yasar A., Koksoy E. B., Urun M., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, (Özet Bildiri) identifier

66. Predictive factors of lymph node metastasis in patients with non-metastatic colorectal adenocarcinoma

Karci E., Koksoy E. B., Alkan A., Dede I., Tuncay G., Utkan G., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri) identifier

67. Severe Drug Interactions and Potentially Inappropriate Medication Usage in Elderly Cancer Patients

ALKAN A., YAŞAR H. A., KARCI E., KÖKSOY E. B., ÜRÜN M., ÇAY ŞENLER F., et al.
ASCO, 6 - 10 Haziran 2016

68. Persistent postmastectomy pain syndrome and posttraumatic stress disorder among breast cancer survivors ORTHUS study A study of the palliative care working committee of the Turkish Oncology Group TOG

ALKAN A., Güç Z. G., ÇAY ŞENLER F., YAVUZŞEN T., Onur H., Doğan M., et al.
Annual Meeting of ASCO, Amerika Birleşik Devletleri, 1 - 04 Haziran 2016, (Özet Bildiri)

69. Mesenchymal stem cell directed baculoviral gene therapy of colon cancer.

Akbulut H., Aktas S. H., Elçin A. E., Parmaksız M., Keskin A. A., Cihan A. C., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) identifier

70. Severe drug interactions and potentially inappropriate medication usage in elderly patients with cancer.

Alkan A., Yasar A., Karci E., Koksoy E. B., Urun M., Senler F. C., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) identifier

71. Persistent postmastectomy pain syndrome and posttraumatic stress disorder among breast cancer survivors (ORTHUS study): A study of the palliative care working committee of the Turkish Oncology Group (TOG).

Alkan A., Guc Z. G., Senler F. C., YAVUZŞEN T., Onur H., Dogan M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) identifier

72. Nadir bir vaka: Akciğer ve kolonda senkron multiple primer tumor

YAŞAR H. A., budak B., ALKAN A., AKBULUT H.
6. Türk Tıbbi Onkoloji kongresi, Antalya, Türkiye, 23 - 27 Mart 2016, ss.454, (Özet Bildiri)

73. Tam Remisyondaki opere meme kanseri hastalarında postmastektomi ağrı sendromu ile post traumatic stress bozukluğu ilişkisi (ORTHUS Çalışması)- Tük Onkoloji Grubu Destek Tedaviler Grubu

ALKAN A., Güç Z. G., ÇAY ŞENLER F., YAVUZŞEN T., onur H., Doğan M., et al.
6.Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 23 - 27 Mart 2016, ss.142, (Özet Bildiri)

74. Geriatrik kanser hastalarında ciddi ilaç etkileşimi ve uygunsuz ilaç kullanımı

ALKAN A., YAŞAR H. A., KARCI E., KÖKSOY E. B., ürün m., ÇAY ŞENLER F., et al.
6.Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 23 - 27 Mart 2016, ss.167, (Özet Bildiri)

75. The Effect of Melatonin Curcumin and Salermide on Sirt2 expression Level of Hippocampus in Middle Aged Rats

AKBULUT K. G., KESKİN AKTAN A., Mutlu Ç., AKBULUT H.
41st National Physiology Congress, Türkiye, 12 - 14 Eylül 2015

76. Prognostic factors for survival in patients with metastatic melanoma treated with ipilimumab: Turkish Oncology Group (TOG) Study

ÜRÜN Y., Abali H., Turna H., Esin E., Sedef A. M., Alkan A., et al.
European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri) identifier

77. The significance of the serum leptin, ghrelin, tumor necrosis factor alpha and interleukine-1 levels in patients with non-small cell lung cancer

Karatas F., Yalcin B., AKBULUT H., Utkan G., Sahin S., DEMİRKAZIK A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

78. Sequential use of bevacizumab and cetuximab in patients with K-RAS wild type advanced colorectal cancer.

AKBULUT H., Gercik O., Icli F., Mizrak D., DEMİRKAZIK A., Onur H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

79. The survival rate at 5 years in Turkish metastatic melanoma patients treated with ipilimumab: Final analysis of MIPI-TURK

Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Mandel N. M., Demir G., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

80. 4 1 7 Endüstri ve Teknoloji Kanser Araştırmaları ve tedavilerini ne kadar etkiliyor

AKBULUT H.
Ulusal Kanser kongresi, Türkiye, 25 - 27 Nisan 2015, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

81. Nutrition foods poultry meat and cancer

AKBULUT H.
Third international poultry meat congress, 22 - 26 Nisan 2015 Sürdürülebilir Kalkınma

82. Preoperative systemic therapy for locally advanced breast cancer single center experience

MIZRAK KAYA D., Kubilay P., Berna K., Onur H., AKBULUT H.
San Antonio Breast Cancer Conference, 9 - 13 Aralık 2014 Sürdürülebilir Kalkınma

83. Serum levels of CEA and CA 15 3 in different subtypes of recurrent breast cancer

MIZRAK KAYA D., Öztürk B., Kubilay P., AKBULUT H., Onur H.
San Antonio Breast Cancer Conference, 9 - 13 Aralık 2014 Sürdürülebilir Kalkınma

84. More prognostic factors in early stage breast cancer

MIZRAK KAYA D., Öztürk B., Kubilay P., AKBULUT H., Onur H.
san Antonio Breast Cancer Conference, 9 - 13 Aralık 2014 Sürdürülebilir Kalkınma

85. Effect of tumor hormonal and HER2 status on localization of metastases in recurrent breast cancer

MIZRAK KAYA D., Onur H., Öztürk B., Kubilay P., AKBULUT H.
San Antonio Breast Cancer Conference, 9 - 13 Aralık 2014 Sürdürülebilir Kalkınma

86. Effect of HER2 and hormonal status to FDG uptake on PET CT imaging in recurrent breast cancer

MIZRAK KAYA D., Onur h., öztürk b., pınar k., UTKAN G., AKBULUT H.
SanAntonio Breast Cancer Conference, 9 - 13 Aralık 2014 Sürdürülebilir Kalkınma

87. Blood group is it associated with tumor biology in breast cancer

MIZRAK KAYA D., Öztürk B., Kubilay P., AKBULUT H., Onur H.
San Antonio Breast Cancer Conference, 9 - 13 Aralık 2014 Sürdürülebilir Kalkınma

88. Correlation of tumor marker levels with intensity of FDG uptake on PET imaging in epithelial cancers.

Mizrak D., ARAZ M., AKBULUT H., KÜÇÜK N. Ö., Alkan A., Yalcin S., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

89. Over kanserli hastalarda serum CA125 düzeyi ile 18F-FDG-PET/BT pozitifliği arasındaki ilişkinin saptanması

Mızrak D., ARAZ M., AKBULUT H., Kubilay P., ALKAN A., KÜÇÜK N. Ö., et al.
5.Türk Tıbbi Onkoloji Kongresi, Türkiye, 19 - 23 Mart 2014, (Özet Bildiri) Sürdürülebilir Kalkınma

90. Metastatik kolorektal kanserli hastalarda serum CEA düzeyleri ile 18F- FDG-PET/BT pozitifliği ilişkisi

Mızrak D., ARAZ M., ALKAN A., AKBULUT H., KÜÇÜK N. Ö., İÇLİ F.
5.Türk Tıbbi Onkoloji Kongresi, Türkiye, 19 - 23 Mart 2014, (Özet Bildiri) Sürdürülebilir Kalkınma

91. Meme kanserli hastalarda serum CEA ve CA 15-3 düzeyleri ile 18F-FDG PET/BT pozitifliği arasındaki ilişki

Mızrak D., ARAZ M., AKBULUT H., ÖZTÜRK B., ALKAN A., KÜÇÜK N. Ö., et al.
5.Türk Tıbbi Onkoloji Kongresi, Türkiye, 19 - 23 Mart 2014, (Özet Bildiri) Sürdürülebilir Kalkınma

92. Is anemia due to chronic disease the main cause of anemia in cancer patients?

Utkan G., Kenar G., AKBULUT H., DEMİRKAZIK A., Onur H., Icli F.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

93. The vascular endothelial growth factor as a predictive and prognostic factor in patients with advanced gastric cancer treated with docetaxel, cisplatin, and 5-florouracil (DCF) regimen.

Aktas S. H., AKBULUT H., Yazici O., Zengin N., Akgun N., Ustuner Z., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

94. Serum CEA and CA 15-3 levels according to breast cancer subtypes

Dede I., Utkan G., AKBULUT H., ÜRÜN Y., Mizrak D., Icli F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

95. Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK at 30 months of follow-up.

Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Demir G., Gokmen E., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) identifier

96. Wnt1 gene expression alters heterogeneous population of prostate cancer cells; decreased expression pattern observed in CD133(+)/CD44(+)prostate cancer stem cells

Goksei G., Bilir A., Uslu R., AKBULUT H., Guven U., ÖKTEM G.
104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, Kiribati, 6 - 10 Nisan 2013, cilt.73, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

97. FIGHTING AGAINST CIGARETTE SMOKING AMONG MEDICAL STUDENTS-A SUCCESS STORY

Icli F., ODABAŞ D., Gonullu İ., AKBULUT H., Ozkan A., Olmez S., et al.
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 28 Eylül - 02 Ekim 2012, ss.469, (Özet Bildiri) identifier

98. Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK.

Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Demir G., Gokmen E., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) identifier

99. ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.

ÜRÜN Y., Koru-Sengul T., Altundag K., Utkan G., Onur H., AKBULUT H., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

100. Smoking habits of relatives of patients (pts) with cancer.

Hayran M., Kilickap S., ELKIRAN E. T., AKBULUT H., Abali H., Yuce D., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

101. The Significance of the Serum Leptin Ghreline Tumor Necrosis Factor Alpha and Interleukine 1 Levels in Patient With Non Small Cell Lung Cancer

ÜRÜN Y., YALÇIN B., KARATAŞ F., UTKAN G., YÜKSEL C., CANGIR A., et al.
The 2011 European Multidisiplinary Cancer Congress. Stockholm, Sweden, Stockholm, İsveç, 24 - 27 Eylül 2011, ss.612

102. The Significance of the Serum Leptin, Ghreline, Tumour Necrosis Factor Alpha and Interleukine-1 Levels in Patients With Non-Small Cell Lung Cancer

ÜRÜN Y., Yalcin B., Karatas F., Utkan G., YÜKSEL C., Cangir A., et al.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47, (Özet Bildiri) Sürdürülebilir Kalkınma identifier identifier

103. Status of Granulocyte Colony-Stimulating Factor Receptor in Tumour Tissue of Patients With Breast Cancer

Yalcin B., Gunaydin Y., Percinel S., Dogan M., ÜRÜN Y., Ozal F. G., et al.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

104. Relationship Between ABO and RH Blood Groups and K-Ras Phenotype in Patients With Colorectal Adenocarcinoma

ÜRÜN Y., Utkan G., Arslan O., AKBULUT H., Savas B., Senler F. C., et al.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47, (Özet Bildiri) identifier

105. The role of serum osteopontin (OPN) as a prognostic and predictive marker in patients with advanced gastric cancer.

YAZICI O., AKBULUT H., Akgün N., UTKAN G., YALÇIN B., İÇLİ F.
ASCO 2011, 2 - 06 Haziran 2011, (Özet Bildiri) Sürdürülebilir Kalkınma

106. The Chemotherapeutic DRUGS at the Metronomic Doses Decrease Vascular ENDOTHELIAL GROWTH FACTOR (VEGF) Secretion of SOLID TUMORS

Aktas H. E., AKBULUT H., Akgun N.
9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Türkiye, 4 - 08 Eylül 2010, cilt.42, ss.162-163, (Özet Bildiri) identifier

107. Melatonin Decreases DNA Fragmantation and Oxidative STRESS PARAMETERS of Gastrointestinal Mucosa

AKBULUT K. G., AKBULUT H., Akgun N.
9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Türkiye, 4 - 08 Eylül 2010, cilt.42, ss.99-100, (Özet Bildiri) identifier

108. The role of Phe329 in the inhibition of human butyrylcholinesterase by malachite green and methyl green

Biberoglu K., Tacal O., AKBULUT H.
35th Congress of the Federation-of-European-Biochemical-Societies, Gothenburg, İsveç, 26 Haziran - 01 Temmuz 2010, cilt.277, ss.81, (Özet Bildiri) identifier

109. Inhibition of A277V mutant of human butyrylcholinesterase by malachite green

Biberoglu K., Tacal O., AKBULUT H.
34th Congress of the Federation-of-European-Biochemical-Societies, Prague, Çek Cumhuriyeti, 4 - 09 Temmuz 2009, cilt.276, ss.130, (Özet Bildiri) identifier

110. GM CSF augments tumor specific immune response and anti tumoral efficacy when combined with suicide gene therapy

AKBULUT H., ÇÖLERİ CİHAN A., AÇIKGÖZ N., ŞAHİN G., BAYDIN P., TANG Y., et al.
45th ASCO Annual Meeting, Orlando, 29 Mayıs - 02 Haziran 2009, cilt.27 Sürdürülebilir Kalkınma

111. Effect of GM-CSF on tumor-specific immune response and antitumoral efficacy when combined with suicide gene therapy

AKBULUT H., Coleri A., Acikgoz N., Sahin G., Ozkal P., Tang Y., et al.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2009, cilt.27, (Özet Bildiri) identifier

112. Kronik Viral Hepatitlerde Lenfoproliferatif Hastalıklar

BOZKUŞ Y., İDİLMAN R., MIZRAK KAYA D., CENGİZ SEVAL G., Saykı M., Üstün Y., et al.
25. Ulusal Gastroenteroloji Haftası, Türkiye, 12 - 16 Kasım 2008, (Tam Metin Bildiri)

113. Vector Prime-Protein Boost Vaccine induces 20 Fold Decrease in the Levels of CD44(+)CD24(-/Low) Cancer Stem Cells in Epithelial Neoplasms

Tang Y., AKBULUT H., Maynard J., Li P., Deisseroth A. B.
50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium, San-Francisco, Kostarika, 6 - 09 Aralık 2008, cilt.112, ss.1000, (Özet Bildiri) identifier

114. TAA/ecdCD40L VPP Vaccination Induces Robust Adaptive Immune Response Even in Individuals with Post Transplantation Lymphopenia

Tang Y., Park Y. H., Maynard J., Li P., AKBULUT H., Petersen L., et al.
50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2008, cilt.112, ss.141-142, (Özet Bildiri) identifier

115. Vaccine for prevention of breast cancer.

Deisseroth A., Tang Y., Maynard J., AKBULUT H.
42nd Annual Meeting of the American-Society-of-Clinical-Oncology, Georgia, Amerika Birleşik Devletleri, 2 - 06 Haziran 2006, cilt.24, (Özet Bildiri) identifier

116. Hepatitis B and C seroprevalance in cancer patients: A case control study

Utkan G., Azap A., Muallaoglu S., Tokluoglu S., Durnali A. G., Arslan U. Y., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.297, (Özet Bildiri) identifier

117. Vector targeted chemotherapy plus vector vaccination can cure solid tumors

AKBULUT H., Tang Y., Akbulut G. K., Maynard J., Deisseroth A. B.
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.143, (Özet Bildiri) identifier

118. Vector prime-protein boost vaccine induces immune response against "self-antigens" associated with epithelial neoplasms and tumor vascular endothelial cells.

Tang Y., Maynard J., AKBULUT H., Linton P., Deisseroth A.
47th Annual Meeting of the American-Society-of-Hematology, Georgia, Amerika Birleşik Devletleri, 10 - 13 Aralık 2005, cilt.106, (Özet Bildiri) identifier

119. The evaluation of the hydrotalcite effectiveness on prophylaxis and treatment of mucositis due to high dose methotrexate treatment in osteosarcoma patients: A prospective crossover trial.

Utkan G., Tek I., Doruk H., Yalcin B., Buyukcelik A., AKBULUT H., et al.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri) identifier

120. Irinotecan plus oral etoposide (IRET) combination is an highly active and promising treatment in heavily pre-treated small cell lung cancer patients.

AKBULUT H., Tek I., Demirkazik A., Icli F., Doruk H., Yalcin B., et al.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

121. The relationship between serum cholesterol level and axillary lymph node statu in breast cancer patients

Utkan G., Onur H., Akbulut H., Yalcin B., Buyukcelik A., Tek I., et al.
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 11 Aralık 2005, cilt.94, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

122. Divided doses of cisplatin in combination with gemcitabine for patients with advanced non-small cell lung cancer (NSCLC).

Demirkazik A., Yalcin B., AKBULUT H., Buyukcelik A., Cay F., Utkan G., et al.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

123. Addition of 2 cycles of EP (Etoposide plus Cisplatin) to the 4 cycles of adjuvant AC (doxorubicin plus cyclophosphamide) improves the survival in node positive patients with breast cancer after 10 years

Icli F., AKBULUT H., Dincol D., Onur H., Demirkazik A., Cam R., et al.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

124. The prognostic role of serum telomerase activity in advanced breast cancer receiving anthracyclines.

AKBULUT H., Temizkan S., Arican A., Zengin N., Yalcin B., Icli F.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

125. Vector vaccine overcomes anergy.

Deisseroth A., Tang Y., Zhang L., AKBULUT H., Linton P.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) identifier

126. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells

zhang l., Tang Y., AKBULUT H., Zelterman D., linton P., Deisseroth A.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, 6 - 08 Aralık 2003, (Özet Bildiri) Sürdürülebilir Kalkınma

127. An adenoviral vector cancer vaccine that delivers a tumor associated antigen/CD40-ligand fusion protein to dendritic cells in vivo and thereby breaks tolerance to tumor associated self antigens.

Tang Y., Zhang L., AKBULUT H., Litton P., Deisseroth A.
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 Aralık 2003, cilt.102, (Özet Bildiri) identifier

128. Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with hematological malignancies

Idilman R., Arat M., TÖRÜNER M., Soykan I., Karayalcin S., Soydan E., et al.
38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Türkiye, 29 Mart - 01 Nisan 2003, cilt.38, ss.146-147, (Özet Bildiri) Sürdürülebilir Kalkınma identifier
Kitaplar 5

1. Kanser Biyolojisi

Babahan C., Sonugür F. G., Akbulut H.
İç Hastalıkları, İliçin Gürler,Biberoğlu Kadir,Süleymanlar Gültekin,Ünal Serhat, Editör, Güneş Tıp Kitabevi, Ankara, ss.1659-1670, 2024

2. Viral Vektör Aşıları

Sonugür F. G., Babahan C., Akbulut H.
Aşı Çalışmaları ve Teknolojisi, Mert Döşkaya,Adnan Yüksel Gürüz,Ayşe Gülten Kantarcı,Cemal Ün, Editör, Nobel Tıp Kitabevi, Ankara, ss.355-382, 2023

3. Hedefe Yönelik Ajanlar ve COVID-19

Köksoy E. B., Akbulut H.
Kanser ve COVID-19 Pandemisi, Yalçın Ş,Özet A, Editör, Türkiye Klinikleri, Ankara, ss.95-100, 2020

4. Kanserde Gen Tedavisi

Aktaş S. H., Baydın P., Akbulut H.
Kanser, Prof. Dr. Mustafa Altınbaş, Editör, DNT Ortadoğu Yayıncılık, Ankara, ss.1372-1383, 2016

5. Prevention of Cervical Cancer: Chemoprevention

Akbulut H., Deisseroth A.
Progress in Oncology 2002, DeVita V,Hellman S,Rosenberg SA, Editör, Jones and Barlett Publishers , Massachusetts, ss.251-269, 2002
Metrikler

Yayın

345

Yayın (WoS)

225

Yayın (Scopus)

194

Atıf (WoS)

1898

H-İndeks (WoS)

22

Atıf (Scopus)

2028

H-İndeks (Scopus)

23

Atıf (Scholar)

264

H-İndeks (Scholar)

6

Atıf (TrDizin)

4

H-İndeks (TrDizin)

2

Atıf (Diğer Toplam)

10

Proje

33

Fikri Mülkiyet

1

Tez Danışmanlığı

18

Açık Erişim

32
BM Sürdürülebilir Kalkınma Amaçları